AI assistant
Sending…
EBOS GROUP LIMITED — Director's Dealing 2017
Dec 20, 2017
64813_rns_2017-12-20_a65069ce-52ab-4676-8cf0-4563e575f379.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [98 x 27] intentionally omitted <==
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
| To NZX Limited; and | ||
|---|---|---|
| Name of listed issuer: | EBOS GroupLimited | |
| Date this disclosure made: | 20-Dec-17 | |
| Date of last disclosure: | 22-Sep-17 | |
| Director or senior manager giving disclosure | ||
| Full name(s): | Michael Broome | |
| Name of listed issuer: | EBOS GroupLimited | |
| Name of related body corporate (if applicable): | N/A | |
| Position held in listed issuer: | Group General Manager, HCL & Symbion | |
| Contract Logistics | ||
| Summary of acquisition or disposal of relevant interest (excluding specified derivatives) | ||
| Class ofaffected quotedfinancialproducts: | Ordinaryshares in EBOS GroupLimited | |
| Nature ofthe affectedrelevantinterest(s): | Sale of shares on-market | |
| For that relevant interest- | ||
| Number held in class before acquisition or disposal: | 1,714 ordinaryshares | |
| Number held in class after acquisition or disposal: | Nil | |
| Current registered holder(s): | Michael Wynston Broome | |
| Registeredholder(s) once transfers areregistered: | N/A | |
| Summary of acquisition or disposal of specified derivatives relevant interest (ifapplicable) | ||
| Type of affected derivative: | N/A | |
| Class of underlyingfinancialproducts: | N/A | |
| Details of affected derivative- | ||
| The notional value of the derivative (if any) or the notional amount of underlying financial | ||
| products(if any): | N/A | |
| A statement as to whether the derivative is cash settled orphysicallysettled: | N/A | |
| Maturitydate of the derivative(if any): | N/A | |
| Expirydate of the derivative(if any): | N/A | |
| Theprice specified in the terms of the derivative(if any): | N/A | |
| Any other details needed to understand how the amount of the consideration payable | ||
| under the derivative or the value of the derivative is affected by the value of the | ||
| underlyingfinancialproducts: | N/A | |
| _For that derivative,- _ | ||
| Parties to the derivative: | N/A | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant | ||
| interestinthe derivative: | N/A | |
| Details of transactions giving rise to acquisition or disposal | ||
| Total numberoftransactions towhich noticerelates: | 3 | |
| Details of transactions requiring disclosure- | ||
| Date oftransaction: | 18-Dec-17 | |
| Nature oftransaction: | Sale of shares on-market | |
| Name ofany otherparty orparties to the transaction(if known): | N/A | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition | ||
| or disposal. If the consideration was not in cash and cannot be readily by converted into a | ||
| cash value,describe the consideration: | $31,238.66 | |
| Numberof financialproducts towhichthe transaction related: | 1,714 ordinaryshares | |
| If the issuer has a financial products trading policy that prohibits directors or senior | ||
| managers from trading during any period without written clearance (a closed period) | ||
| include the following details— | ||
| Whether relevantinterestswere acquired ordisposed ofduring a closed period: | No |
| Whether prior written clearance was provided to allow the acquisition or disposal toproceed duringthe closedperiod: | Whether prior written clearance was provided to allow the acquisition or disposal toproceed duringthe closedperiod: | Whether prior written clearance was provided to allow the acquisition or disposal toproceed duringthe closedperiod: | ||||
|---|---|---|---|---|---|---|
| N/A | ||||||
| Date of theprior written clearance(if any): | N/A | |||||
| Summary of other relevant interests after acquisition or disposal: | ||||||
| Class ofquotedfinancialproducts: | ||||||
| Nature of relevant interest: | ||||||
| _For that relevant interest,- _ | ||||||
| Number heldinclass: | 1. 40,000 ordinary shares2. 40,000 ordinaryshares | |||||
| Currentregisteredholder(s): | Michael Broome | |||||
| _For a derivative relevant _ | interest,- | N/A | ||||
| Type ofderivative: | N/A | |||||
| Details of derivative,- | ||||||
| The notional value of the derivative (if any) or the notional amount of underlying financialproducts (if any): | N/A | |||||
| A statement as to whether the derivative is cash settled or physically settled: | N/A | |||||
| Maturity date of the derivative (if any): | N/A | |||||
| Expiry date of the deriva | tive (if any): | N/A | ||||
| The price's specified ter | ms (if any): | N/A | ||||
| Any other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of theunderlyingfinancialproducts: | to understand how the amount of the consideratiohe value of the derivative is affected by the value of | n payablethe | N/A | |||
| For that derivative relevant interest,- | N/A | |||||
| Parties to the derivative: | N/A | |||||
| If the director or senior manager is not a party to the derivative, the nature of the relevantinterest in the derivative: | N/A | |||||
| Certification | ||||||
| I certify that, to the bestdisclosure is correct andfor whom it is made. | of my knowledge and belief, the information contained in thisthat I am duly authorised to make this disclosure by all persons | |||||
| 20-Dec-17Janelle Cain, General Counsel, EBOS GroupLimited | ||||||
| Signature of director or o | fficer: | |||||
| Date of signature: | ||||||
| or | ||||||
| Signature of person auth | orised to sign on behalf of director or officer: | |||||
| Date of signature: | ||||||
| Name and title of author | ised person: | |||||
More from EBOS GROUP LIMITED
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Capital/Financing Update
2026
May 6
Share Issue/Capital Change
2026
May 5
Capital/Financing Update
2026
May 5
Regulatory Filings
2026
May 1